NRSN Company Profile and Key Details

NeuroSense Therapeutics Ltd. has 24.60 million shares outstanding. The public float is 12.54 million shares, elevated short interest at 2.84% of float. This equals 579.23 thousand shares. The short ratio is 2.55 days. Institutional investors hold 2.56% of the float. Insiders own 29.68%.

NRSN has shown mixed momentum, losing -0.97% over the past week and -14.29% over the past quarter, though year-to-date performance is up 32.64%. Short-term trend indicators are mixed aligned (SMA20 -3.22%, SMA50 -0.84%, SMA200 -30.26%). The stock’s 14-day RSI is 47.64 (neutral), while the ATR of 0.08 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -65.32% below its high and over 32.6% above its low. Average 10-day trading volume of 261.33 thousand shares is slightly above the 3-month average of 235.89 thousand, indicating heightened recent market interest.

NeuroSense Therapeutics Ltd. generated EPS of -$0.58 over the past year. Five-year average earnings growth is 2.71%. Wall Street analysts project EPS growth of 28.41% annually over the next five years. The latest quarter delivered EPS of -$0.04. The next quarter is forecast at -$0.10. Next year's EPS is expected at -$0.61. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 7 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $14.00 to $3.00. The high target offers 1718.18% upside. The low target suggests 289.61% downside. The mean target is $12.43. This offers 1514.29% upside. NeuroSense Therapeutics Ltd. earnings surprise history is a mixed track record. The quarter that ended December 17, 2025, missed forecasts by 0.0%. The prior quarter beat by 0.0%. Over the last six quarters, Apple has recorded several small beats. These include -31.25% in December 18, 2024.

NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) closed at $0.77 USD, losing -$0.04 (-5.36%) from the previous close of $0.82. The stock is currently mid-range between its 52-week high and low $0.68 and $2.60. With a market capitalization of about $19.10 million, NeuroSense Therapeutics Ltd. is classified as a micro-cap and shows higher-than-market volatility (beta ~1.61). Key stats such as the average daily volume over the past year has been around 229.20 thousand shares, in line with its 52-week average. Headquartered in Herzliya, None, NeuroSense Therapeutics Ltd. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Alon Ben-Noon, the company employs approximately 17 people and listed since December 09, 2021. NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of treatment for patients suffering from debilitating neurodegenerative diseases.

NeuroSense Therapeutics Ltd. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.18. This means the shares are trading above this model’s fair value.

NeuroSense Therapeutics Ltd. trades at a P/E ratio of -2.3, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of -38.41 indicating negative book value, which may reflect financial stress. The P/FCF stands at -9679.2, also below market averages.

NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) shares are up 32.64% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows NeuroSense Therapeutics Ltd. trading at a premium to the broader market with a P/E of -2.3. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $11.81, suggesting 1424.85% upside. Our AI forecast model points to short-term weakness (-4.45% over two weeks), a medium-term rise (78.18% over three months), and a longer-term gain (69.14% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that NeuroSense Therapeutics Ltd. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -4.45%, with price expected at $0.74 by April 01, 2026, within a range of $0.69 to $0.79 3-Month Outlook: Projected rise of 78.18%, reaching $1.38 by June 16, 2026, with a range of $1.28 to $1.47. 1-Year Outlook: Projected gain of 69.14%, with price at $1.31 by March 18, 2027, within a range of $0.00 to $0.00.